prednisolone and Airflow Obstruction, Chronic studies

Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.

Research Excerpts

Excerpt	Relevance	Reference
"Seventeen COPD patients (forced expiratory volume in 1 second 50%-80% predicted) using short-acting bronchodilators participated in a double-blind, double-dummy, randomized, crossover study."	6.75	A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. ( Borrill, Z; Singh, D; Smyth, L; Sweeney, L; Tal-Singer, R, 2010)
"This study demonstrates that besides lung function impairment systemic inflammation manifested by elevated fibrinogen levels is an independent risk factor for exacerbations of COPD."	5.13	Increased systemic inflammation is a risk factor for COPD exacerbations. ( Groenewegen, KH; Hop, WC; Postma, DS; Schlösser, NJ; Wielders, PL; Wouters, EF, 2008)
" The pattern of hyperglycemia induced by prednisolone has not been well characterized."	3.77	Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. ( Aguilar-Loza, NR; Burt, MG; Frith, P; Roberts, GW; Stranks, SN, 2011)
"The aim of this study was to evaluate the effect of calcitriol on bone mass in patients with corticosteroid induced osteoporosis."	3.72	Effect of rocaltrol on bone mass in patients with pulmonary disease treated with corticosteroids. ( Hahn, M; Knoll, P; Köhn, H; Levi, M; Mirzaei, S; Pohl, W; Zajicek, HK, 2003)
"Despite a far lower cumulative GC dose in comparison with patients treated with systemic corticosteroids continuously, after adjusting for BMI and lung function, osteoporosis of the lumbar spine was most frequent in patients receiving > 1,000 mg of prednisolone cumulatively, administered in multiple courses for the treatment of exacerbations of COPD."	3.71	Dual energy X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens. ( Dekhuijzen, PN; Dubois, EF; Röder, E; Schweitzer, DH; Zwinderman, AE, 2002)
"A total of 150 patients with COPD, non-CF bronchiectasis or asthma, and P."	3.11	Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? ( Alispahic, IA; Andreassen, HF; Armbruster, K; Bangsborg, J; Bodtger, U; Browatzki, A; Christensen, CW; Coia, JE; Datcu, R; Eklöf, J; Ellingsgaard, T; Fenlev, CS; Ghathian, KSA; Gundersen, L; Harboe, ZB; Heidemann, M; Janner, J; Jensen, JUS; Jensen, TT; Johansson, SL; Johnsen, S; Kjærgaard, JL; Lapperre, TS; Linde, H; Moberg, M; Nielsen, TL; Overgaard, RH; Pedersen, L; Rosenvinge, FS; Saeed, MI; Seersholm, N; Sivapalan, P; Sørensen, VM; Titlestad, I; Ulrik, CS; Vijdea, R; Weinreich, UM; Wilcke, T; Østergaard, C, 2022)
"Most patients with mild to severe chronic obstructive pulmonary disease (COPD) experience exacerbations, which are also associated with increased healthcare costs."	2.90	Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial. ( Bosmans, JE; Finch, AP; Prins, JM; Sterk, PJ; Ter Riet, G; van Velzen, P, 2019)
"Our finding suggests that COPD patients experience improvements in exercise tolerance from a single high dose of glucocorticoid even in the stable phase of their disease."	2.90	A single administration of glucocorticoid increases exercise capacity in men with stable chronic obstructive pulmonary disease. ( Backer, V; Godtfredsen, N; Karlsson, SL, 2019)
"In patients with mild-to-severe COPD receiving treatment for an exacerbation in an outpatient setting, the antibiotic doxycycline added to the oral corticosteroid prednisolone did not prolong time to next exacerbation compared with prednisolone alone."	2.84	Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial. ( Baars, JJ; Bresser, P; Brinkman, P; Dagelet, JWF; Daniels, JMA; Groeneveld-Tjiong, DRGL; Jonkers, RE; Krouwels, FH; Pool, K; Prins, JM; Rudolphus, A; Sterk, PJ; Ter Riet, G; van den Berg, BTJ; van den Berg, JWK; van Kan, C; van Velzen, P, 2017)
"The symptoms of COPD, forced expiratory volume in one second (FEV1) and other spirometric indicators, peripheral blood oxygen saturation (SpO2), and adverse events were studied."	2.82	[Nebulized budesonide in the treatment of exacerbations of chronic obstructive pulmonary disease: Efficacy, safety, and effects on the serum levels of soluble differentiation molecules]. ( Czapaeva, MY; Karaulov, AV; Kazatskaya, ZA; Lazareva, ES; Makarova, EV; Menkov, NV; Novikov, VV; Varvarina, GN, 2016)
"Data of 70 COPD patients in the STG and 72 patients in the control group (CG) were analysed."	2.82	(Cost-)effectiveness of self-treatment of exacerbations in patients with COPD: 2 years follow-up of a RCT. ( Brusse-Keizer, M; Effing, T; Kerstjens, HA; van der Palen, J; van der Valk, P; Zielhuis, G; Zwerink, M, 2016)
"Acute exacerbations of COPD (AE-COPD) often result in administration of antibiotics although more than half of exacerbations are associated with detection of respiratory viruses and potentially pathogenic bacteria can only be detected in 20-30% of cases."	2.80	Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD--the ABACOPD study. ( Koch, A; Rohde, GG; Welte, T, 2015)
"Twenty-eight stable COPD patients had their ILPs and FEV1 measured both before and 2 h after the use of a single dose of 18 mcg bronchodilator tiotropium and 50 mcg salmeterol."	2.79	Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD. ( Dekhuijzen, PN; Heijdra, YF; Hop, WC; Ramlal, SK; Visser, FJ, 2014)
"Exacerbations of chronic obstructive pulmonary disease (COPD) and responses to treatment are heterogeneous."	2.77	Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. ( Bafadhel, M; Barer, MR; Brightling, CE; Johnston, SL; Lomas, DA; McKenna, S; Mistry, V; Pancholi, M; Pavord, ID; Terry, S; Venge, P, 2012)
"Chronic obstructive pulmonary disease (COPD) patients with a FEV1/FVC ratio <0."	2.77	Effects of extra-fine inhaled and oral corticosteroids on alveolar nitric oxide in COPD. ( Lipworth, BJ; Short, PM; Williamson, PA, 2012)
"This study suggests that in AECOPD, IV MP followed by oral MP produced greater improvement in FEV(1) and PEF than IV HC followed by oral prednisolone, although there were no differences in need for ventilator support or in recurrence of exacerbation."	2.76	Efficacy of two corticosteroid regimens in acute exacerbation of chronic obstructive pulmonary disease. ( Aggarwal, P; Bhoi, S; Wig, N, 2011)
"Seventeen COPD patients (forced expiratory volume in 1 second 50%-80% predicted) using short-acting bronchodilators participated in a double-blind, double-dummy, randomized, crossover study."	2.75	A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. ( Borrill, Z; Singh, D; Smyth, L; Sweeney, L; Tal-Singer, R, 2010)
"Nine percent to 16% of the COPD population was classified as responder, depending on the international guideline criteria used."	2.74	Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. ( Akkermans, RP; Chavannes, NH; Dekhuijzen, RP; Muris, JW; Schermer, TR; van Schayck, OC; van Weel, C; Wouters, EF, 2009)
"Chronic obstructive pulmonary disease (COPD) is a chronic disease with a high prevalence and rapidly increasing incidence rates."	2.74	(Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study. ( Effing, T; Kerstjens, H; van der Palen, J; van der Valk, P; Zielhuis, G, 2009)
"Effects of inhaled budesonide in COPD are not restricted to patients with severe disease and may be linked to a suppression of eosinophilic inflammation."	2.73	Long-term effects of budesonide on inflammatory status in COPD. ( Boorsma, M; Jansen, HM; Jonkers, RE; Lutter, R; Out, TA; van de Pol, MA, 2008)
"Prednisolone testing is an unreliable predictor of the benefit from inhaled fluticasone propionate in individual patients."	2.71	Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. ( Anderson, JA; Burge, PS; Calverley, PM; Jones, PW; Spencer, S, 2003)
"Time to the next COPD exacerbation did not differ in one large study that was powered to detect non-inferiority and compared five days versus 14 days of systemic corticosteroid treatment (n = 311; hazard ratio 0."	2.58	Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. ( Tan, DJ; Walters, JA; White, CJ; Wood-Baker, R, 2018)
"Time to the next COPD exacerbation did not differ in one large study that was powered to detect non-inferiority and compared five days versus 14 days of systemic corticosteroid treatment (n = 311; hazard ratio 0."	2.50	Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. ( Tan, DJ; Walters, JA; White, CJ; Wood-Baker, R, 2014)
"The definitions of asthma and COPD in international guidelines leave some space to misdiagnosing."	2.48	[COPD and Asthma: same same but different]. ( Rothe, T, 2012)
"No study specified COPD diagnostic criteria and only one specified exacerbation criteria."	2.47	Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. ( Morley, C; Soltani, A; Walters, JA; Wang, W; Wood-Baker, R, 2011)
"COPD is a disease of the small airways (SA)."	1.72	COPD is associated with increased pro-inflammatory CD28null CD8 T and NKT-like cells in the small airways. ( Asare, PF; Hodge, G; Hodge, S; Holmes, M; Jayapal, M; Jersmann, H; Reynolds, PN; Tran, HB, 2022)
"Patients with a history of chronic obstructive pulmonary disease (COPD) or asthma undergoing surgery are at risk for developing postoperative pulmonary complications, associated with morbidity and mortality."	1.72	[Dutch guideline to prevent perioperative pulmonal complications: how is the adherence?] ( Bronsveld, I; Kappen, T; Marsman, M; Miggelbrink, LA; Senff, JR; van Klei, W; van Waes, JAR, 2022)
"COPD is a progressive inflammatory disease of the lungs, characterized by acute exacerbations that may lead to increased mortality."	1.72	A 4-Year Retrospective Claims Analysis of Oral Corticosteroid Use and Health Conditions in Newly Diagnosed Medicare FFS Patients with COPD. ( Alston, M; Bazell, C; Caplen, M; Comellas, AP; Feigler, N; Hansen, D; Pollack, M; Pyenson, B; Sethi, S; Staresinic, A; Styczynski, J, 2022)
"People with opioid use disorder (OUD) may be at particular risk, however, there have been no case-control studies of asthma care and outcomes in this patient group."	1.56	A primary care database study of asthma among patients with and without opioid use disorders. ( Hulin, J; Mitchell, C; Oliver, P, 2020)
"A short-course oral steroid treatment for Chronic Obstructive Pulmonary Disease (COPD) exacerbation had been administered four weeks prior to the presentation."	1.56	Strongyloides stercoralis hyperinfection syndrome presenting as mechanical ileus after short-course oral steroids for chronic obstructive pulmonary disease (COPD) exacerbation. ( Braren, R; Busch, DH; Katchanov, J; Phillip, V; Rothe, K; Schmid, RM; Schneider, J; Slotta-Huspenina, J; Spinner, CD; Tappe, D, 2020)
"Allergy was the most frequent indication (20."	1.56	High prescription rate of oral glucocorticoids in children and adults: A retrospective cohort study from Western Sweden. ( Einarsdottir, MJ; Ekman, P; Johannsson, G; Olsson, DS; Ragnarsson, O; Trimpou, P, 2020)
"The results showed the patients with AECOPD with good and poor response to standard corticosteroid treatment have a distinct DNA methylation pattern."	1.48	Whole-genome methylation profiling of peripheral blood mononuclear cell for acute exacerbations of chronic obstructive pulmonary disease treated with corticosteroid. ( Chen, CH; Chuang, TY; Hsu, PW; Lee, SW; Liu, CW; Weng, JT; Wu, LS, 2018)
"Blood was collected from COPD (n = 10) and aged-matched controls (n = 10)."	1.43	Steroid resistance in COPD is associated with impaired molecular chaperone Hsp90 expression by pro-inflammatory lymphocytes. ( Hodge, G; Hodge, S; Holmes, M; Jersmann, H; Reynolds, PN; Roscioli, E; Tran, HB, 2016)
"Nine patients suffered from chronic obstructive pulmonary disease (COPD) before treatment, and 18 patients had a smoking history (median pack years: 48)."	1.43	Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy - a single-centre experience. ( Bremer, M; Christiansen, H; Dickgreber, N; Henkenberens, C; Janssen, S; Lavae-Mokhtari, M; Leni, K; Meyer, A, 2016)
"Our results revealed that COPD was significantly associated with a high risk of osteoporosis, regardless of whether the patients with COPD were corticosteroid users and irrespective of age and sex."	1.42	Chronic obstructive pulmonary disease and allied conditions is a strong independent risk factor for osteoporosis and pathologic fractures: a population-based cohort study. ( Chang, KH; Chen, SJ; Huang, KH; Kao, CH; Kung, PT; Liao, WC; Lin, CL; Tsai, WC, 2015)
"Lymphocyte senescence in COPD is associated with loss of HDAC2 in CD28nullCD8+ T and NKT-like cells."	1.42	Lymphocyte senescence in COPD is associated with decreased histone deacetylase 2 expression by pro-inflammatory lymphocytes. ( Hodge, G; Hodge, S; Holmes, M; Jersmann, H; Reynolds, PN; Roscioli, E; Tran, HB, 2015)
"Patients with chronic obstructive pulmonary disease have a high risk of osteoporosis and fractures."	1.38	[Diagnosing and treating osteoporosis in patients with chronic obstructive pulmonary disease]. ( Abrahamsen, B; Brask-Lindemann, D; Eiken, PA; Langdahl, BL; Vestbo, J, 2012)
" However, the most appropriate dosage regimen has not been determined and remains controversial."	1.38	COPD exacerbations in general practice: variability in oral prednisolone courses. ( Berendsen, AJ; Bosveld, HE; de Vries, M; Kerstjens, HA; van der Molen, T, 2012)
"Patients with asthma or COPD exacerbation are often hospitalised directly after a telephone consultation with their primary doctor or an A&E doctor."	1.38	Hospitalisations due to exacerbation of asthma and COPD. ( Arstad, F; Melbye, H; Moe, PC, 2012)
"EBC pH is lower in COPD than in healthy control non-smokers, but does not differentiate COPD from smokers without COPD, relate to disease severity or to airway inflammation, and does not respond to corticosteroids."	1.37	Evaluation of exhaled breath condensate pH as a biomarker for COPD. ( Edwards, LD; Hunt, JF; Locantore, NW; MacNee, W; Miller, BE; Rennard, SI; Tal-Singer, R, 2011)
"Patients with asthma or COPD (n = 198), who were hepatitis B surface antigen-seropositive and had been treated with ICS, were identified retrospectively."	1.36	Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids. ( Chang, YS; Cho, SH; Kim, KM; Kim, MN; Kim, SH; Kim, TW; Kim, W; Kim, YY; Kwon, JW; Min, KU; Park, HW, 2010)
"In the rat model of chronic obstructive pulmonary disease, the dilatation effect of prednisolon was most obvious after 15 days of nitrogen dioxide inhalation."	1.36	[Broncholytic effect of prednisolon in the rats inhaled with nitrogen dioxide]. ( Danilov, LN; Fedin, AN; Krivchenko, AI; Kuzubova, NA; Lebedeva, ES; Postnikova, TIu, 2010)
"COPD is characterised by damage to small airways due to an inflammatory process as well as an imbalance between oxidants and antioxidants."	1.33	Markers of inflammation and oxidative stress in exacerbated chronic obstructive pulmonary disease patients. ( Asin, J; Gerritsen, WB; Haas, FJ; van den Bosch, JM; Zanen, P, 2005)
"Approximately 5-10% of COPD is attributable to non-smoking causes including occupational exposures."	1.33	A 26-year-old welder with severe non-reversible obstructive lung disease. ( Balkissoon, R, 2006)
"Treatment of chronic obstructive pulmonary disease (COPD) exacerbations improves outcomes; however, responses to treatment are variable, and patients with COPD often delay presentation or fail to seek therapy."	1.32	Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. ( Donaldson, GC; Hurst, JR; Seemungal, TA; Wedzicha, JA; Wilkinson, TM, 2004)
"Thirty-six hospitalised COPD patients with an acute exacerbation and 10 healthy volunteers were included."	1.32	Reduced spontaneous apoptosis in peripheral blood neutrophils during exacerbation of COPD. ( Burkhardt, O; de Roux, A; Ioanas, M; Lode, H; Pletz, MW, 2004)
"75 patients with COPD were enrolled in the open study (mean 57,76 years of age; 32 smokers, reversible obstruction <15%)."	1.32	[Quality of life in patients with chronic obstructive pulmonary disease before and after the treatment with prednisone]. ( Bijata-Bronisz, R; Dziedziczko, A, 2004)
"inhibition: 97."	1.32	Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. ( Beeh, KM; Beier, J; Buhl, R; Lerch, C; Schulz, AK, 2004)
"It is concluded that in severe chronic obstructive pulmonary disease, maintenance treatment with oral glucocorticoids is associated with increased mortality in a dose-dependent manner."	1.31	Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. ( de Vries, G; Kester, AD; Mostert, R; Schols, AM; Slangen, J; Wesseling, G; Wouters, EF, 2001)
"Chronic obstructive pulmonary disease (COPD) is characterised by both an accelerated decline in lung function and periods of acute deterioration in symptoms termed exacerbations."	1.31	Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. ( Bhowmik, A; Donaldson, GC; Seemungal, TA; Wedzicha, JA, 2002)

Research

Studies (82)

Authors

Clinical Trials (29)

Trial Overview

Trial Outcomes

Difference of Hospitalization Rate

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.22)	18.7374
1990's	0 (0.00)	18.2507
2000's	32 (39.02)	29.6817
2010's	38 (46.34)	24.3611
2020's	11 (13.41)	2.80

Authors	Studies
Kaviani, A	1
Khansari Nejad, N	1
Akour, A	1
AlMuhaissen, SA	1
Nusair, MB	1
Al-Tammemi, AB	1
Mahmoud, NN	1
Jalouqa, S	1
Alrawashdeh, MN	1
Shanahan, JP	1
Moore, CM	1
Kampf, JW	1
Szymczak, NK	1
Guo, J	1
Wang, H	1
Luo, Y	1
An, H	1
Zhang, Z	2
Liu, G	1
Li, J	1
Metcalfe, GD	1
Smith, TW	1
Hippler, M	1
Ayala Izurieta, JE	1
Márquez, CO	1
García, VJ	1
Jara Santillán, CA	1
Sisti, JM	1
Pasqualotto, N	1
Van Wittenberghe, S	1
Delegido, J	1
Kubo, Y	1
Kitagawa, Y	1
Miyazaki, T	1
Sohda, M	1
Yamaji, T	1
Sakai, M	1
Saeki, H	1
Nemoto, K	1
Oyama, T	2
Muto, M	1
Takeuchi, H	1
Toh, Y	1
Matsubara, H	1
Mano, M	1
Kono, K	1
Kato, K	1
Yoshida, M	1
Kawakubo, H	1
Booka, E	1
Yamatsuji, T	1
Kato, H	1
Ito, Y	1
Ishikawa, H	1
Ishihara, R	1
Tsushima, T	1
Kawachi, H	1
Kojima, T	1
Kuribayashi, S	1
Makino, T	1
Matsuda, S	1
Doki, Y	1
Ma, P	1
Tang, X	1
Zhang, L	2
Wang, X	1
Wang, W	2
Zhang, X	2
Wang, S	2
Zhou, N	1
Dodd, J	1
Jordan, R	1
Makhlina, M	1
Pesco Koplowitz, L	1
Koplowitz, B	1
Barnett, K	1
Yang, WH	1
Spana, C	1
Buchanan, SW	1
Mafa-Attoye, T	1
Dunfield, K	1
Thevathasan, NV	1
Isaac, ME	1
Wu, X	2
Huang, JW	1
Su, BK	1
Yuan, L	1
Zheng, WQ	1
Zhang, H	2
Zheng, YX	1
Zhu, W	1
Chou, PT	1
Manso, AP	1
De Morais, DC	1
Yamamoto, K	1
Owen, G	1
de Carvalho, RM	1
Palma-Dibb, RG	1
Brown, JC	1
Yang, S	1
Mire, EF	1
Miele, L	1
Ochoa, A	1
Zabaleta, J	1
Katzmarzyk, PT	1
Moi, CT	1
Bhowmick, S	1
Qureshi, M	1
Wang, K	1
Feng, B	1
Yang, Y	1
Chen, Y	1
Wang, Y	2
Yang, L	1
Jiang, K	1
James, TD	1
Chaturvedi, V	1
Postiglione, WM	1
Chakraborty, RD	1
Yu, B	1
Tabiś, W	1
Hameed, S	1
Biniskos, N	1
Jacobson, A	1
Zhou, H	1
Greven, M	1
Ferry, VE	1
Leighton, C	1
Wu, F	1
Lei, H	1
Chen, G	1
Chen, C	1
Song, Y	1
Cao, Z	1
Zhang, C	2
Zhou, J	1
Lu, Y	1
Pappone, C	1
Santinelli, V	1
Mecarocci, V	1
Tondi, L	1
Ciconte, G	1
Manguso, F	1
Sturla, F	1
Vicedomini, G	1
Micaglio, E	1
Anastasia, L	1
Pica, S	1
Camporeale, A	1
Lombardi, M	1
Shieh, PB	1
Elfring, G	1
Trifillis, P	1
Santos, C	1
Peltz, SW	1
Parsons, JA	1
Apkon, S	1
Darras, BT	1
Campbell, C	1
McDonald, CM	1
Galaviz, KI	1
Shah, NS	1
Gutierrez, M	1
Collins, LF	1
Lahiri, CD	1
Moran, CA	1
Szabo, B	1
Sumitani, J	1
Rhodes, J	1
Marconi, VC	1
Nguyen, ML	1
Cantos, VD	1
Armstrong, WS	1
Colasanti, JA	1
Hodge, G	3
Jersmann, H	3
Tran, HB	3
Asare, PF	1
Jayapal, M	1
Reynolds, PN	3
Holmes, M	3
Hodge, S	3
Ng, KH	1
Chen, DY	1
Lin, CH	1
Chao, WC	1
Chen, HH	1
Eklöf, J	1
Alispahic, IA	1
Sivapalan, P	1
Wilcke, T	1
Seersholm, N	1
Armbruster, K	1
Kjærgaard, JL	1
Saeed, MI	1
Nielsen, TL	1
Browatzki, A	1
Overgaard, RH	1
Fenlev, CS	1
Harboe, ZB	1
Andreassen, HF	1
Lapperre, TS	1
Pedersen, L	1
Johnsen, S	1
Ulrik, CS	1
Janner, J	1
Moberg, M	1
Heidemann, M	1
Weinreich, UM	1
Vijdea, R	1
Linde, H	1
Titlestad, I	1
Johansson, SL	1
Rosenvinge, FS	1
Østergaard, C	1
Ghathian, KSA	1
Gundersen, L	1
Christensen, CW	1
Bangsborg, J	1
Jensen, TT	1
Sørensen, VM	1
Ellingsgaard, T	1
Datcu, R	1
Coia, JE	1
Bodtger, U	1
Jensen, JUS	1
Bazell, C	1
Pollack, M	1
Comellas, AP	1
Sethi, S	1
Alston, M	1
Pyenson, B	1
Hansen, D	1
Caplen, M	1
Staresinic, A	1
Styczynski, J	1
Feigler, N	1
Miggelbrink, LA	1
Marsman, M	1
Senff, JR	1
van Waes, JAR	1
Bronsveld, I	1
van Klei, W	1
Kappen, T	1
Einarsdottir, MJ	1
Ekman, P	1
Trimpou, P	1
Olsson, DS	1
Johannsson, G	1
Ragnarsson, O	1
Griffiths, P	1
Kumar, A	1
Liatsikos, K	1
Rothe, K	1
Katchanov, J	1
Schneider, J	1
Spinner, CD	1
Phillip, V	1
Busch, DH	1
Tappe, D	1
Braren, R	1
Schmid, RM	1
Slotta-Huspenina, J	1
Oliver, P	1
Hulin, J	1
Mitchell, C	1
Kuzeva, A	1
Dost, S	1
Lams, B	1
Agarwal, S	1
Furmedge, DS	1
van Velzen, P	2
Ter Riet, G	2
Bresser, P	1
Baars, JJ	1
van den Berg, BTJ	1
van den Berg, JWK	1
Brinkman, P	1
Dagelet, JWF	1
Daniels, JMA	1
Groeneveld-Tjiong, DRGL	1
Jonkers, RE	2
van Kan, C	1
Krouwels, FH	1
Pool, K	1
Rudolphus, A	1
Sterk, PJ	2
Prins, JM	2
Peh, HY	1
Tan, WSD	1
Chan, TK	1
Pow, CW	1
Foster, PS	1
Wong, WSF	1
Karlsson, SL	2
Backer, V	2
Godtfredsen, NS	1
Lee, SW	1
Weng, JT	1
Hsu, PW	1
Chuang, TY	1
Liu, CW	1
Chen, CH	1
Wu, LS	1
Walters, JA	3
Tan, DJ	2
White, CJ	2
Wood-Baker, R	3
Finch, AP	1
Bosmans, JE	1
Godtfredsen, N	1
Nadesalingam, K	1
Kirby, D	1
Ramlal, SK	1
Visser, FJ	1
Hop, WC	2
Dekhuijzen, PN	2
Heijdra, YF	1
Budweiser, S	1
Bafadhel, M	2
Davies, L	1
Calverley, PM	2
Aaron, SD	1
Brightling, CE	3
Pavord, ID	3
Chen, SJ	1
Liao, WC	1
Huang, KH	1
Lin, CL	1
Tsai, WC	1
Kung, PT	1
Chang, KH	1
Kao, CH	1
Rohde, GG	1
Koch, A	1
Welte, T	1
Roscioli, E	2
Zwerink, M	1
Kerstjens, HA	4
van der Palen, J	2
van der Valk, P	2
Brusse-Keizer, M	1
Zielhuis, G	2
Effing, T	2
Henkenberens, C	1
Janssen, S	1
Lavae-Mokhtari, M	1
Leni, K	1
Meyer, A	1
Christiansen, H	1
Bremer, M	1
Dickgreber, N	1
Makarova, EV	1
Varvarina, GN	1
Menkov, NV	1
Czapaeva, MY	1
Lazareva, ES	1
Kazatskaya, ZA	1
Novikov, VV	1
Karaulov, AV	1
Kunal, S	1
Pilaniya, V	1
Jain, S	1
Shah, A	1
Bathoorn, E	1
Liesker, JJ	1
Postma, DS	3
Boorsma, M	2
Bondesson, E	1
Koëter, GH	1
Kauffman, HF	1
van Oosterhout, AJ	1
Ställberg, B	1
Selroos, O	1
Vogelmeier, C	1
Andersson, E	1
Ekström, T	1
Larsson, K	1
Kerstjens, H	1
Daniels, JM	1
Snijders, D	1
de Graaff, CS	1
Vlaspolder, F	1
Jansen, HM	2
Boersma, WG	1
Singh, D	1
Smyth, L	1
Borrill, Z	1
Sweeney, L	1
Tal-Singer, R	3
Chavannes, NH	1
Schermer, TR	1
Wouters, EF	3
Akkermans, RP	1
Dekhuijzen, RP	1
Muris, JW	1
van Weel, C	1
van Schayck, OC	1
Fedin, AN	1
Kuzubova, NA	1
Danilov, LN	1
Lebedeva, ES	1
Postnikova, TIu	1
Krivchenko, AI	1
Kim, TW	1
Kim, MN	1
Kwon, JW	1
Kim, KM	1
Kim, SH	1
Kim, W	1
Park, HW	1
Chang, YS	1
Cho, SH	1
Min, KU	1
Kim, YY	1
Sin, DD	1
Miller, BE	2
Duvoix, A	1
Man, SF	1
Silverman, EK	1
Connett, JE	1
Anthonisen, NA	1
Wise, RA	1
Tashkin, D	1
Celli, BR	1
Edwards, LD	2
Locantore, N	1
Macnee, W	2
Lomas, DA	2
Rennard, SI	1
Hunt, JF	1
Locantore, NW	1
Burt, MG	1
Roberts, GW	1
Aguilar-Loza, NR	1
Frith, P	1
Stranks, SN	1
Aggarwal, P	1
Wig, N	1
Bhoi, S	1
Füessl, HS	1
Morley, C	1
Soltani, A	1
de Vries, M	1
Berendsen, AJ	1
Bosveld, HE	1
van der Molen, T	2
Rothe, T	1
Short, PM	1
Williamson, PA	1
Lipworth, BJ	1
McKenna, S	1
Terry, S	1
Mistry, V	1
Pancholi, M	1
Venge, P	2
Barer, MR	1
Johnston, SL	1
Melbye, H	1
Moe, PC	1
Arstad, F	1
Eiken, PA	1
Brask-Lindemann, D	1
Vestbo, J	1
Langdahl, BL	1
Abrahamsen, B	1
Walsh, LJ	1
Lewis, SA	1
Wong, CA	1
Cooper, S	1
Oborne, J	1
Cawte, SA	1
Harrison, T	1
Green, DJ	1
Pringle, M	1
Hubbard, R	1
Tattersfield, AE	1
Donaldson, GC	2
Seemungal, TA	2
Bhowmik, A	1
Wedzicha, JA	2
Mirzaei, S	1
Zajicek, HK	1
Knoll, P	1
Hahn, M	1
Levi, M	1
Köhn, H	1
Pohl, W	1
Burge, PS	1
Jones, PW	1
Spencer, S	1
Anderson, JA	1
LECKIE, WJ	1
HORNE, NW	1
Robinson, DS	1
Campbell, DA	1
Durham, SR	1
Pfeffer, J	1
Barnes, PJ	1
Chung, KF	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Targeted AntiBiotics for Chronic Pulmonary Disease: Can Targeted Antibiotic Therapy Improve the Prognosis of Pseudomonas Aeruginosa Infected Patients With Chronic Pulmonary Obstructive Disease, Non-cystic Fibrosis Bronchiectasis and Asthma? A Multicenter,[NCT03262142]	Phase 4	51 participants (Actual)	Interventional	2018-01-10	Terminated (stopped due to Slow recruitment)
Phase I/II Randomized, Double-blind, Placebo-controlled Cross-over Study of Prednisone on Airway Inflammatory Response to Inhaled Wood Smoke.[NCT03861390]	Phase 1/Phase 2	14 participants (Anticipated)	Interventional	2019-03-22	Recruiting
Randomized Double Blind Placebo-controlled Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD - The ABACOPD Study[NCT01892488]	Phase 4	295 participants (Actual)	Interventional	2013-06-07	Completed
Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Non-small Cell Lung Cancer Patients[NCT03803787]	Phase 2	72 participants (Anticipated)	Interventional	2018-09-01	Recruiting
Effects of High Dose Inhaled Budesonide+ Formoterol Versus Placebo and Oral Prednisolone on Biomarkers of Airway Inflammation in the Treatment of Exacerbations in Non-hospitalised Patients With Mild to Moderate COPD.[NCT00239278]	Phase 2	120 participants	Interventional	2001-01-31	Completed
A Randomised, Double Blind, Double Dummy, Multicentre Phase III Study Comparing the Efficacy of Budesonide/Formoterol (Symbicort® Forte Turbuhaler®) and Oral Prednisolone + Formoterol (Oxis® Turbuhaler) During Two Weeks, in COPD Patients With an Acute Exa[NCT00259779]	Phase 3	120 participants (Anticipated)	Interventional	2005-09-30	Completed
The Value of Antibiotic Treatment of Exacerbations of Hospitalised COPD Patients[NCT00170222]	Phase 4	258 participants (Anticipated)	Interventional	2002-07-31	Completed
CRP-guided Antibiotic Treatment in Patients Hospitalized With Acute Exacerbations of COPD Patients. A Randomized Controlled Intervention Trial.[NCT01232140]		220 participants (Anticipated)	Interventional	2011-07-31	Recruiting
A Randomised, Double-blind, Double-dummy, Placebo-controlled, Five-way Crossover Study to Assess the Effects of Single Oral Doses of SB-681323 (7.5 mg and 25 mg) and Prednisolone (10 mg and 30 mg) on Biomarkers in Induced Sputum and Blood in COPD Patients[NCT00380133]	Phase 1	20 participants (Actual)	Interventional	2005-06-30	Completed
A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time[NCT00292552]		2,747 participants (Actual)	Observational	2005-12-31	Completed
Efficacy and Safety of Oral Corticosteroids for the Treatment of Acute Exacerbations of COPD in General Practice[NCT02330952]	Phase 4	189 participants (Actual)	Interventional	2015-02-10	Completed
Does Extra-fine HFA-BDP Suppress Small Airways Inflammation in COPD?[NCT00921921]	Phase 4	16 participants (Actual)	Interventional	2009-06-30	Completed
"Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD - a Randomized, Double-blind, Non-inferiority Study (The RECUT-Trial)"[NCT02386735]		470 participants (Anticipated)	Interventional	2015-03-31	Recruiting
A Prospective Baseline Assessment of the Risk of Osteoporosis in Patients With Chronic Obstructive Lung Disease and Outcomes After 2 Years; a Pilot Study[NCT01161680]		30 participants (Actual)	Observational	2010-07-31	Completed
Impact of the Artificial Intelligence (Machine Learning) in a Telemonitoring Programme of COPD Patients With Multiple Hospitalizations (telEPOC)[NCT04978922]		345 participants (Anticipated)	Interventional	2018-01-01	Recruiting
Morphological Parameters of Blood Cell's Activation in Characterization and Prognosis in a COPD Patients Cohort[NCT04923360]		500 participants (Anticipated)	Observational [Patient Registry]	2018-01-01	Recruiting
Phase 4 Withdrawal of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease in Primary Care: a Randomised Controlled Trial[NCT00440687]	Phase 4	256 participants	Interventional	2001-01-31	Completed
Studying the Airway Microenvironment in Patients Undergoing Surgical and Bronchoscopic Interventions for COPD[NCT03010592]		80 participants (Anticipated)	Observational	2017-02-06	Recruiting
Monitoring COPD Patients at Home by a Forced Oscillation Technique Device[NCT01552031]		80 participants (Anticipated)	Observational	2011-11-30	Recruiting
A Phase II Study to Investigate Mannitol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD[NCT00117182]	Phase 2	140 participants	Interventional	2005-07-31	Completed
Retrospective Review on Patients With Recurrent Asthmatic Attacks Requiring Hospitalizations[NCT04479501]		2,280 participants (Actual)	Observational	2017-12-01	Completed
A 3 Year Longitudinal Study of the Level of Asthma Control and Treatment of Asthma Patients in Hong Kong[NCT03239431]		400 participants (Anticipated)	Observational [Patient Registry]	2017-09-15	Recruiting
Evaluation of the Performance of an e-Health System Comprising Tele-monitoring / Tele-notification and Tele-coaching in Ambulatory Multi-morbid Adult Patients[NCT02803489]		23 participants (Actual)	Interventional	2016-04-08	Terminated (stopped due to inclusion rate too low & investigators enable to recruit new patients rapidly)
Clinical Implementation and Outcomes Evaluation of Blood-Based Biomarkers for Chronic Obstructive Pulmonary Disease Management[NCT02050022]		522 participants (Actual)	Observational	2013-04-30	Active, not recruiting
Clinical Trials for Elderly Patients With Multiple Disease[NCT01960907]		312 participants (Actual)	Interventional	2013-10-31	Completed
Biomarkers and Clinical Characteristics That Identify the Risk of an Exacerbation Following Viral Upper Respiratory Tract Infections in COPD Patients[NCT01376830]		35 participants (Actual)	Observational	2011-06-30	Completed
Antibiotic Stewardship Through CRP-guided Antibiotic Treatment for Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)[NCT05286918]		1,184 participants (Anticipated)	Interventional	2022-09-01	Not yet recruiting
A Comparison of Intravenous Versus Oral Administration of Prednisolone in the Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease[NCT00311961]	Phase 4	256 participants	Interventional	2001-06-30	Completed
[NCT01865500]	Phase 4	100 participants (Actual)	Interventional	2013-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Difference between the hospitalization rate during the study and the previous year. For each patient, hospitalization rate was defined as the number of hospital admissions during a period divided by the length (in days) of the period. Number of hospitalizations was collected by the hospital clinical records. (NCT01960907)
Timeframe: Baseline and 9 months

Final Utility Index of EQ-5D Questionnaire

Intervention	hospitalizations/year/patient (Median)
Monitored, Previously Hopitalized for COPD Exacerbation	-1
Observational, Previously Hopitalized for COPD Exacerb.	-1

The quality of life of patients as quantified by the final utility index of the EQ-5D questionnaire. The utility index ranges from -0.074 to 1 with 1 being the highest possible quality of life. (NCT01960907)
Timeframe: 9 months

Time to First Hospitalization

Intervention	units on a scale (Mean)
Observational	0.640
Interventional	0.637

It represents the number of days, since the enrolment into the study, to the first hospitalization (NCT01960907)
Timeframe: From enrolment up to 9 months

Article	Year
Biomaterial investigations in dentistry, 2021, Volume: 8, Issue:1 Topics: Adult; Alcohol Drinking; Ammonia; Animals; Anti-Inflammatory Agents; Area Under Curve; B-Lymphocytes	2021
Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. The Cochrane database of systematic reviews, 2018, 03-19, Volume: 3 Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Disease Progression; Drug Administration Schedu	2018
Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. The European respiratory journal, 2014, Volume: 44, Issue:3 Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Disease Progression; Eosinophils; Female; Human	2014
Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. The Cochrane database of systematic reviews, 2014, Dec-10, Issue:12 Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Disease Progression; Drug Administration Schedu	2014
Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. The Cochrane database of systematic reviews, 2011, Oct-05, Issue:10 Topics: Adrenal Cortex Hormones; Aged; Disease Progression; Drug Administration Schedule; Glucocorticoids; H	2011
[COPD and Asthma: same same but different]. Praxis, 2012, Feb-15, Volume: 101, Issue:4 Topics: Anti-Inflammatory Agents; Asthma; Bronchodilator Agents; Communication Barriers; Comorbidity; Diagno	2012
Achilles tendon rupture associated with combination therapy of levofloxacin and steroid in four patients and a review of the literature. Foot & ankle international, 2007, Volume: 28, Issue:12 Topics: Achilles Tendon; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Casts, Surgical; Female; Fol	2007

Article	Year
Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? Trials, 2022, Sep-27, Volume: 23, Issue:1 Topics: Anti-Bacterial Agents; Asthma; beta-Lactams; Bronchiectasis; Ciprofloxacin; Fibrosis; Humans; Predni	2022
Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial. The Lancet. Respiratory medicine, 2017, Volume: 5, Issue:6 Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Disease Progression; Dou	2017
Oral prednisolone for 4 days does not increase exercise tolerance in men with COPD. Chronic respiratory disease, 2018, Volume: 15, Issue:2 Topics: Aged; Double-Blind Method; Exercise Test; Exercise Tolerance; Forced Expiratory Volume; Glucocortico	2018
Doxycycline Added to Prednisolone in Outpatient-Treated Acute Exacerbations of COPD: A Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial. PharmacoEconomics, 2019, Volume: 37, Issue:5 Topics: Aged; Cohort Studies; Cost-Benefit Analysis; Doxycycline; Drug Therapy, Combination; Female; Humans;	2019
A single administration of glucocorticoid increases exercise capacity in men with stable chronic obstructive pulmonary disease. Danish medical journal, 2019, Volume: 66, Issue:1 Topics: Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Forced Expiratory	2019
Effects of long-acting bronchodilators and prednisolone on inspiratory lung function parameters in stable COPD. Pulmonary pharmacology & therapeutics, 2014, Volume: 28, Issue:2 Topics: Administration, Oral; Aged; Aged, 80 and over; Albuterol; Bronchodilator Agents; Delayed-Action Prep	2014
Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD--the ABACOPD study. BMC pulmonary medicine, 2015, Jan-27, Volume: 15 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Ampicillin; Bronchodilator Agents; Disease Progressio	2015
(Cost-)effectiveness of self-treatment of exacerbations in patients with COPD: 2 years follow-up of a RCT. Respirology (Carlton, Vic.), 2016, Volume: 21, Issue:3 Topics: Adult; Aged; Contraindications; Cost of Illness; Cost-Benefit Analysis; Dose-Response Relationship,	2016
[Nebulized budesonide in the treatment of exacerbations of chronic obstructive pulmonary disease: Efficacy, safety, and effects on the serum levels of soluble differentiation molecules]. Terapevticheskii arkhiv, 2016, Volume: 88, Issue:3 Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Antigens, CD; Bronchodilator Agents; Bud	2016
Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations. COPD, 2008, Volume: 5, Issue:5 Topics: Administration, Inhalation; Administration, Oral; Aged; Anti-Inflammatory Agents; Bronchodilator Age	2008
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respiratory research, 2009, Feb-19, Volume: 10 Topics: Administration, Inhalation; Administration, Oral; Aged; Ambulatory Care; Bronchodilator Agents; Bude	2009
(Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study. Thorax, 2009, Volume: 64, Issue:11 Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Cost-Benefit Analysis; Disease Progres	2009
Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2010, Jan-15, Volume: 181, Issue:2 Topics: Acute Disease; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial In	2010
Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2010, Jan-15, Volume: 181, Issue:2 Topics: Acute Disease; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial In	2010
Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2010, Jan-15, Volume: 181, Issue:2 Topics: Acute Disease; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial In	2010
Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2010, Jan-15, Volume: 181, Issue:2 Topics: Acute Disease; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial In	2010
A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. Journal of clinical pharmacology, 2010, Volume: 50, Issue:1 Topics: Aged; Anti-Inflammatory Agents; Biomarkers, Pharmacological; Female; HSP27 Heat-Shock Proteins; Huma	2010
Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International journal of chronic obstructive pulmonary disease, 2009, Volume: 4 Topics: Administration, Oral; Adult; Aged; Female; Glucocorticoids; Humans; Male; Middle Aged; Netherlands;	2009
Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2011, May-01, Volume: 183, Issue:9 Topics: Anti-Inflammatory Agents; Biomarkers; Chemokines, CC; Cohort Studies; Enzyme-Linked Immunosorbent As	2011
Efficacy of two corticosteroid regimens in acute exacerbation of chronic obstructive pulmonary disease. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2011, Volume: 15, Issue:5 Topics: Acute Disease; Administration, Oral; Aged; Drug Therapy, Combination; Female; Follow-Up Studies; For	2011
Effects of extra-fine inhaled and oral corticosteroids on alveolar nitric oxide in COPD. Lung, 2012, Volume: 190, Issue:4 Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Aged; Biomarkers; Cross-O	2012
Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. American journal of respiratory and critical care medicine, 2012, Jul-01, Volume: 186, Issue:1 Topics: Aged; Aged, 80 and over; Biomarkers; Disease Progression; Eosinophils; Female; Glucocorticoids; Huma	2012
Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax, 2003, Volume: 58, Issue:8 Topics: Administration, Oral; Androstadienes; Bronchodilator Agents; Female; Fluticasone; Forced Expiratory	2003
Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respiratory research, 2006, Apr-07, Volume: 7 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Disease Progression;	2006
Comparison of oral and depot intra-muscular steroids in assessing steroid-responsiveness in COPD. COPD, 2004, Volume: 1, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Delayed-Action Preparations; Double-Blind Method; Fem	2004
Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest, 2007, Volume: 132, Issue:6 Topics: Administration, Oral; Aged; Double-Blind Method; Female; Glucocorticoids; Humans; Injections, Intrav	2007
Increased systemic inflammation is a risk factor for COPD exacerbations. Chest, 2008, Volume: 133, Issue:2 Topics: Aged; Anti-Inflammatory Agents; C-Reactive Protein; Disease Progression; Female; Fibrinogen; Forced	2008
Long-term effects of budesonide on inflammatory status in COPD. COPD, 2008, Volume: 5, Issue:2 Topics: Administration, Inhalation; Administration, Oral; Aged; Bronchodilator Agents; Budesonide; Cross-Ove	2008
Changes in inflammatory markers following treatment of acute exacerbations of obstructive pulmonary disease. Respiratory medicine, 2001, Volume: 95, Issue:11 Topics: Acute Disease; Acute-Phase Proteins; Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Blood Protei	2001
Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. American journal of respiratory and critical care medicine, 2002, Mar-01, Volume: 165, Issue:5 Topics: Acute Disease; Administration, Oral; Aged; Budesonide; Double-Blind Method; Female; Forced Expirator	2002

Article	Year
COPD is associated with increased pro-inflammatory CD28null CD8 T and NKT-like cells in the small airways. Clinical and experimental immunology, 2022, 05-12, Volume: 207, Issue:3 Topics: Aged; CD28 Antigens; CD8-Positive T-Lymphocytes; Cyclosporine; Granzymes; Humans; Prednisolone; Pulm	2022
Analysis of risk factors of mortality in rheumatoid arthritis patients with interstitial lung disease: a nationwide, population-based cohort study in Taiwan. RMD open, 2022, Volume: 8, Issue:2 Topics: Arthritis, Rheumatoid; Cohort Studies; Humans; Lung Diseases, Interstitial; Prednisolone; Pulmonary	2022
A 4-Year Retrospective Claims Analysis of Oral Corticosteroid Use and Health Conditions in Newly Diagnosed Medicare FFS Patients with COPD. International journal of chronic obstructive pulmonary disease, 2022, Volume: 17 Topics: Adrenal Cortex Hormones; Aged; Diabetes Mellitus, Type 2; Humans; Hypertension; Insurance Claim Revi	2022
[Dutch guideline to prevent perioperative pulmonal complications: how is the adherence?] Nederlands tijdschrift voor geneeskunde, 2022, 10-20, Volume: 166 Topics: Adrenal Cortex Hormones; Asthma; Guideline Adherence; Humans; Prednisolone; Prednisone; Pulmonary Di	2022
High prescription rate of oral glucocorticoids in children and adults: A retrospective cohort study from Western Sweden. Clinical endocrinology, 2020, Volume: 92, Issue:1 Topics: Adolescent; Adrenal Insufficiency; Adult; Aged; Aged, 80 and over; Asthma; Child; Child, Preschool;	2020
Swyer-James-MacLeod syndrome and pulmonary arteriovenous malformations: a rare combination. BMJ case reports, 2020, Jan-08, Volume: 13, Issue:1 Topics: Aged; Arteriovenous Malformations; Bronchodilator Agents; Cigarette Smoking; Diagnosis, Differential	2020
Strongyloides stercoralis hyperinfection syndrome presenting as mechanical ileus after short-course oral steroids for chronic obstructive pulmonary disease (COPD) exacerbation. Parasitology international, 2020, Volume: 76 Topics: Animals; Female; Humans; Ileus; Middle Aged; Prednisolone; Pulmonary Disease, Chronic Obstructive; S	2020
A primary care database study of asthma among patients with and without opioid use disorders. NPJ primary care respiratory medicine, 2020, 04-20, Volume: 30, Issue:1 Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aftercare; Aged; Anti-Asthmatic	2020
Time-critical administration of corticosteroid rescue therapy for COVID-19 pneumonitis in a ward-based patient with chronic obstructive pulmonary disease. British journal of hospital medicine (London, England : 2005), 2020, 07-02, Volume: 81, Issue:7 Topics: Aged; Betacoronavirus; C-Reactive Protein; Clinical Deterioration; Coronavirus Infections; COVID-19;	2020
Vitamin E isoform γ-tocotrienol protects against emphysema in cigarette smoke-induced COPD. Free radical biology & medicine, 2017, Volume: 110 Topics: Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Cell Movement; Disease Models, Anim	2017
Whole-genome methylation profiling of peripheral blood mononuclear cell for acute exacerbations of chronic obstructive pulmonary disease treated with corticosteroid. Pharmacogenetics and genomics, 2018, Volume: 28, Issue:3 Topics: Adrenal Cortex Hormones; Aged; Albuterol; Bromhexine; CpG Islands; DNA Methylation; Female; Genome,	2018
Bone protection in chronic obstructive pulmonary disease (COPD) patients requiring regular intermittent glucocorticoid therapy. Clinical medicine (London, England), 2013, Volume: 13, Issue:2 Topics: Aged; Bone Density Conservation Agents; Glucocorticoids; Humans; Osteoporosis; Prednisolone; Pulmona	2013
Five days of corticosteroid for exacerbations of COPD. BMJ (Clinical research ed.), 2013, May-28, Volume: 346 Topics: Disease Progression; Glucocorticoids; Humans; Prednisolone; Pulmonary Disease, Chronic Obstructive;	2013
[How to discontinue steroid medication]. MMW Fortschritte der Medizin, 2013, Jun-27, Volume: 155, Issue:12 Topics: Administration, Oral; Adrenal Cortex Hormones; Asthma; Controlled Clinical Trials as Topic; Disease	2013
[In acute exacerbated COPD steroids last over 5 days]. MMW Fortschritte der Medizin, 2013, Oct-24, Volume: 155, Issue:18 Topics: Anti-Inflammatory Agents; Disease Progression; Drug Administration Schedule; Humans; Prednisolone; P	2013
Chronic obstructive pulmonary disease and allied conditions is a strong independent risk factor for osteoporosis and pathologic fractures: a population-based cohort study. QJM : monthly journal of the Association of Physicians, 2015, Volume: 108, Issue:8 Topics: Adult; Age Distribution; Aged; Cohort Studies; Comorbidity; Databases, Factual; Female; Glucocortico	2015
Lymphocyte senescence in COPD is associated with decreased histone deacetylase 2 expression by pro-inflammatory lymphocytes. Respiratory research, 2015, Oct-24, Volume: 16 Topics: Adult; Aged; Case-Control Studies; CD28 Antigens; CD8-Positive T-Lymphocytes; Cellular Senescence; C	2015
Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy - a single-centre experience. Radiation oncology (London, England), 2016, Feb-02, Volume: 11 Topics: Administration, Inhalation; Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell	2016
'Crazy-paving' pattern: an exceptional presentation of cryptogenic organising pneumonia associated with chronic obstructive pulmonary disease. BMJ case reports, 2016, May-06, Volume: 2016 Topics: Adrenergic beta-2 Receptor Agonists; Cryptogenic Organizing Pneumonia; Humans; Male; Mass Chest X-Ra	2016
Steroid resistance in COPD is associated with impaired molecular chaperone Hsp90 expression by pro-inflammatory lymphocytes. Respiratory research, 2016, 10-21, Volume: 17, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Case-Control Studies; CD28 Antigens; Cyclo	2016
[Broncholytic effect of prednisolon in the rats inhaled with nitrogen dioxide]. Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova, 2010, Volume: 96, Issue:3 Topics: Animals; Anti-Inflammatory Agents; Bronchi; Bronchoconstriction; Male; Nitrogen Dioxide; Oxidants, P	2010
Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids. Respirology (Carlton, Vic.), 2010, Volume: 15, Issue:7 Topics: Adult; Aged; Anti-Asthmatic Agents; Asthma; Female; Glucocorticoids; Hepatitis B; Hepatitis B Surfac	2010
Evaluation of exhaled breath condensate pH as a biomarker for COPD. Respiratory medicine, 2011, Volume: 105, Issue:7 Topics: Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Breath Tests; Diagnosis, Differential; Exhalation;	2011
Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Blood Glucose; Blood Glucose Self-Monitoring; Cro	2011
[When sputum turns color]. MMW Fortschritte der Medizin, 2011, Sep-08, Volume: 153, Issue:36 Topics: Adult; Aged; Algorithms; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bronchodilator Agents; Com	2011
COPD exacerbations in general practice: variability in oral prednisolone courses. BMC family practice, 2012, Jan-12, Volume: 13 Topics: Administration, Oral; Cross-Sectional Studies; Drug Administration Schedule; Evidence-Based Medicine	2012
Hospitalisations due to exacerbation of asthma and COPD. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2012, Aug-07, Volume: 132, Issue:14 Topics: Aged; Anti-Bacterial Agents; Asthma; Female; Humans; Male; Patient Admission; Physical Examination;	2012
[Diagnosing and treating osteoporosis in patients with chronic obstructive pulmonary disease]. Ugeskrift for laeger, 2012, Nov-19, Volume: 174, Issue:47 Topics: Absorptiometry, Photon; Algorithms; Critical Pathways; Fractures, Bone; Glucocorticoids; Humans; Ost	2012
The impact of oral corticosteroid use on bone mineral density and vertebral fracture. American journal of respiratory and critical care medicine, 2002, Sep-01, Volume: 166, Issue:5 Topics: Administration, Inhalation; Administration, Oral; Age Distribution; Aged; Aged, 80 and over; Bone De	2002
The impact of oral corticosteroid use on bone mineral density and vertebral fracture. American journal of respiratory and critical care medicine, 2002, Sep-01, Volume: 166, Issue:5 Topics: Administration, Inhalation; Administration, Oral; Age Distribution; Aged; Aged, 80 and over; Bone De	2002
The impact of oral corticosteroid use on bone mineral density and vertebral fracture. American journal of respiratory and critical care medicine, 2002, Sep-01, Volume: 166, Issue:5 Topics: Administration, Inhalation; Administration, Oral; Age Distribution; Aged; Aged, 80 and over; Bone De	2002
The impact of oral corticosteroid use on bone mineral density and vertebral fracture. American journal of respiratory and critical care medicine, 2002, Sep-01, Volume: 166, Issue:5 Topics: Administration, Inhalation; Administration, Oral; Age Distribution; Aged; Aged, 80 and over; Bone De	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, Volume: 57, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Aged; Female; Forced Expiratory Volume; Humans; Lu	2002
Effect of rocaltrol on bone mass in patients with pulmonary disease treated with corticosteroids. The Journal of asthma : official journal of the Association for the Care of Asthma, 2003, Volume: 40, Issue:3 Topics: Absorptiometry, Photon; Aged; Anti-Inflammatory Agents; Bone Density; Calcitriol; Case-Control Studi	2003
PRELIMINARY ASSESSMENT OF DEPTROPINE DIHYDROGEN CITRATE IN CHRONIC AIRWAYS OBSTRUCTION. Thorax, 1965, Volume: 20 Topics: Adolescent; Anti-Allergic Agents; Asthma; Bronchitis; Bronchodilator Agents; Citrates; Drug Therapy;	1965
Systematic assessment of difficult-to-treat asthma. The European respiratory journal, 2003, Volume: 22, Issue:3 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Asthma; Beclomethasone; Female; Glucocorticoi	2003
Systematic assessment of difficult-to-treat asthma. The European respiratory journal, 2003, Volume: 22, Issue:3 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Asthma; Beclomethasone; Female; Glucocorticoi	2003
Systematic assessment of difficult-to-treat asthma. The European respiratory journal, 2003, Volume: 22, Issue:3 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Asthma; Beclomethasone; Female; Glucocorticoi	2003
Systematic assessment of difficult-to-treat asthma. The European respiratory journal, 2003, Volume: 22, Issue:3 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Asthma; Beclomethasone; Female; Glucocorticoi	2003
Steroid-induced myopathy following a single oral dose of prednisolone. Neurology India, 2003, Volume: 51, Issue:4 Topics: Acute Disease; Administration, Oral; Glucocorticoids; Humans; Male; Middle Aged; Prednisolone; Pulmo	2003
Prednisolone response in patients with COPD. Thorax, 2004, Volume: 59, Issue:2 Topics: Bronchodilator Agents; Forced Expiratory Volume; Glucocorticoids; Humans; Prednisolone; Pulmonary Di	2004
[Chronic obstructive pulmonary disease (COPD): diagnosis and treatment]. Deutsche medizinische Wochenschrift (1946), 2004, Mar-05, Volume: 129, Issue:10 Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-Agonists; Beclomethasone; Bronchod	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Aged; Dyspnea; Female; Follow-Up Studies; Forced Expiratory Volume; Glucocorticoids; Hospitalization	2004
Reduced spontaneous apoptosis in peripheral blood neutrophils during exacerbation of COPD. The European respiratory journal, 2004, Volume: 23, Issue:4 Topics: Aged; Apoptosis; Bronchi; Cell Movement; Cell Nucleus; Cell Survival; Cells, Cultured; Female; Flow	2004
Does early treatment of exacerbation improve outcome in chronic obstructive pulmonary disease? American journal of respiratory and critical care medicine, 2004, Jun-15, Volume: 169, Issue:12 Topics: Dyspnea; Forced Expiratory Volume; Glucocorticoids; Hospitalization; Humans; Prednisolone; Pulmonary	2004
[Quality of life in patients with chronic obstructive pulmonary disease before and after the treatment with prednisone]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2004, Volume: 17, Issue:99 Topics: Adult; Aged; Anti-Inflammatory Agents; Attitude to Health; Female; Humans; Male; Middle Aged; Predni	2004
Markers of inflammation and oxidative stress in exacerbated chronic obstructive pulmonary disease patients. Respiratory medicine, 2005, Volume: 99, Issue:1 Topics: Aged; Anti-Inflammatory Agents; Breath Tests; Cell Adhesion Molecules; Drug Monitoring; Female; Huma	2005
Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung, 2004, Volume: 182, Issue:6 Topics: Adult; Asthma; Benzamides; Female; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Predniso	2004
A 26-year-old welder with severe non-reversible obstructive lung disease. COPD, 2006, Volume: 3, Issue:1 Topics: Adult; Anti-Inflammatory Agents; Humans; Lymph Nodes; Male; Pneumoconiosis; Prednisolone; Pulmonary	2006
Oral vs IV corticosteroids for in-hospital treatment of COPD exacerbations. Chest, 2007, Volume: 132, Issue:6 Topics: Administration, Oral; Glucocorticoids; Humans; Injections, Intravenous; Prednisolone; Pulmonary Dise	2007
Vulnerability of gastric mucosa to prednisolone in rats chronically exposed to cigarette smoke. Journal of pharmacological sciences, 2008, Volume: 106, Issue:4 Topics: Alanine; Animals; Anti-Ulcer Agents; Blood Gas Analysis; Dinoprostone; Disease Models, Animal; Gastr	2008
Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. The European respiratory journal, 2001, Volume: 17, Issue:3 Topics: Administration, Oral; Aged; Betamethasone; Dose-Response Relationship, Drug; Female; Follow-Up Studi	2001
[Emergency treatment of acute respiratory disorders in patients with chronic obstructive lung disease and bronchial asthma]. Terapevticheskii arkhiv, 2001, Volume: 73, Issue:4 Topics: Acute Disease; Aminophylline; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Bronchodilato	2001
Dual energy X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens. Chest, 2002, Volume: 121, Issue:5 Topics: Absorptiometry, Photon; Administration, Oral; Aged; Anti-Inflammatory Agents; Body Mass Index; Bone	2002

prednisolone and Airflow Obstruction, Chronic